As Biotech M&A Activity Gingerly Rises, Regeneron Makes Moves On Checkmate

Paying $250m For Vidutolimod Developer

 
• By Ayisha Sharma
Checkmate's Lead Candidate Could Be Best-In-Class • Source: Alamy

More from Deals

More from Business